Financial Results

Key highlights

Filter

Period

Filter by

recent search

Showing: 105 of 24 Financial Results




Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance
Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance

Paris (France), 22 October 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2020.


Ipsen presents its half year 2020 results and reinstates guidance for full year 2020
Ipsen presents its half year 2020 results and reinstates guidance for full year 2020

David Loew, Chief Executive Officer of Ipsen, stated: “I’m honored since July 1st to lead Ipsen, an exciting global biopharma business with solid business fundamentals, a strong purpose to serve patients and attractive growth opportunities. I am encouraged by the exceptional levels…


Your dedicated contacts